These 3 case studies illustrate the challenges of intensifying treatment in complex T2D patients--and also the options available to individualize that next step.
There is significant flexibility now available when it comes to intensifying pharmacologic treatment for patients with type 2 diabetes (T2D). There is also a growing opportunity to individualize T2D treatment, both when changes to a regimen are needed and at initiation of medical therapy.The following 3 patient case studies illustrate a number of the common comorbidities and complications associated with T2D that make effective management like working on a jigsaw puzzle. With recent FDA label expansions for several classes of T2D drugs, however, it is getting easier to find a perfect fit.Based on your knowledge of the drugs and the science, what is the best next Rx for each of these patients - and why?
Tirzepatide Real-World Benefit Found Greater for CV, Renal Outcomes vs GLP-1 RAs in Adults with T2D
August 12th 2024In a head-to-head real world study, tirzepatide compared with semaglutide resulted in 42%, 20%, and 46% reduced risks for all-cause mortality and major adverse CV and renal events, respectively.